- Abstract
- 10.1182/blood.v130.suppl_1.4214.4214
A Novel Lysyl Oxidase Inhibitor Attenuates Bone Marrow Fibrosis and Decreases Spleen Size in a Mouse Model of Primary Myelofibrosis
- Jun 25, 2021
- Blood
- Orly Leiva + 5 more +5
Publications from 2021 to 2026
Showing 8 of 8 papers
A Novel Lysyl Oxidase Inhibitor Attenuates Bone Marrow Fibrosis and Decreases Spleen Size in a Mouse Model of Primary Myelofibrosis
Enforceability of Contract Terms Displayed on Social Media
It is a prerequisite for the use of virtually any social media that the user enter into a contract with the provider. Typically, the user is required to click “OK” or “I accept” at the foot of a lengthy set of online terms and conditions. Sometimes contracts of this nature are described as “clickwrap” or “browsewrap” agreements. Given that a majority of users will typically not read the terms and conditions or, if they do, will feel they have no option but to accept them, and given further that service providers are aware that this is the case, the question arises as to whether and to what extent such terms and conditions are, or should be, in fact, legally enforceable. This chapter explores relevant Australian and overseas case law and commentary dealing with this modern social media legal phenomenon.
Read moreSynthetic Studies on the Natural Product Myrsinoic Acid F Reveal Biologically Active Analogues.
The synthesis of the structure, 1, assigned to the anti-inflammatory natural product myrsinoic acid F is reported together with a means for preparing its Z-isomer 21. While neither of these compounds corresponds to the natural product, both of them are anti-inflammatory agents (as determined using a mouse ear edema assay) with congener 1 being notably more potent than the widely prescribed NSAID indometacin.
Read moreAuthor response: Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis
Matrix stiffening with downstream activation of mechanosensitive pathways is strongly implicated in progressive fibrosis; however, pathologic changes in extracellular matrix (ECM) that initiate mechano-homeostasis dysregulation are not defined in human disease. By integrated multiscale biomechanical and biological analyses of idiopathic pulmonary fibrosis lung tissue, we identify that increased tissue stiffness is a function of dysregulated post-translational collagen cross-linking rather than any collagen concentration increase whilst at the nanometre-scale collagen fibrils are structurally and functionally abnormal with increased stiffness, reduced swelling ratio, and reduced diameter. In ex vivo and animal models of lung fibrosis, dual inhibition of lysyl oxidase-like (LOXL) 2 and LOXL3 was sufficient to normalise collagen fibrillogenesis, reduce tissue stiffness, and improve lung function in vivo. Thus, in human fibrosis, altered collagen architecture is a key determinant of abnormal ECM structure-function, and inhibition of pyridinoline cross-linking can maintain mechano-homeostasis to limit the self-sustaining effects of ECM on progressive fibrosis.
Read moreInhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial
Helping others acquire, license or invest in patents with confidence – A guide for patent searchers to patent due diligence
Dynamic analysis of penetrating trauma.
Notes for Identification of the Winking Owl